Anna Olsson

Anna Olsson has fourteen years of experience in the clinical research field. Anna began their career in 1995 as a Clinical Research Monitor for Merck Sharp & Dohme. In 1996, they moved to Quintiles as a Clinical Trial Coordinator. In 2001, they were promoted to Clinical Project Manager at Quintiles. In 2006, they joined AstraZeneca as a Study Delivery Leader and was later promoted to Study Delivery Program Leader. In 2010, they moved to Promonordic AB as a Clinical Study Manager. In 2011, they joined Sobi - Swedish Orphan Biovitrum AB (publ) as a Clinical Program Leader. In 2019, they were appointed Director of Clinical Development at Infant Bacterial Therapeutics AB. Currently, they are working as a Clinical Project Leader at Gesynta Pharma AB.

Anna Olsson attended Uppsala University from 1988 to 1992, where they earned their MSc in Pharmacist.